Clonazepam: Nursing Drug Guide, Respiratory Depression & Taper Safety

Clonazepam is a Schedule IV benzodiazepine supplied as oral tablets (commonly 0.5 mg, 1 mg, and 2 mg). Verify strength and indication (seizure disorder vs panic disorder) on every administration pass—dose ranges differ by use.

Common U.S. brand example: Klonopin tablets (scored 0.5 mg; unscored 1 mg and 2 mg with K-shaped perforation per labeling). Generic clonazepam is widely dispensed. Do not interchange with other benzodiazepines without prescriber and pharmacy verification.

Clonazepam is used alone or as an adjunct for selected epilepsy syndromes (including Lennox-Gastaut, akinetic, and myoclonic seizures, and some absence seizures after succinimide failure) and for adult panic disorder with or without agoraphobia. It is not first-line for every patient with worry or stress; use the lowest effective dose for the shortest duration and reassess continued need per prescribing information.

↔On a small screen, swipe or scroll sideways to see the full table.

Clonazepam is a 1,4 benzodiazepine that enhances GABA activity at GABA_A receptors; the precise antiseizure and antipanic mechanism is unknown per labeling. Clinical effects include anticonvulsant activity, anxiolysis, sedation, and muscle relaxation. Elimination half-life is typically 30 to 40 hours—sedation and respiratory effects may persist across shifts. Because it depresses central respiratory drive—especially with opioids or alcohol—nurses must treat sedation and respiratory rate as primary safety endpoints, not secondary comfort measures.

Dosing depends on indication, age, hepatic function, and interacting drugs. Verify each order against current prescribing information and the patient’s opioid and CNS depressant exposure before administration.

Missed dose: For seizure patients, contact prescriber/pharmacy before withholding maintenance doses—abrupt gaps can lower seizure threshold. If oversedated or on new opioids, hold and clarify. Do not double doses.

Pretreatment checks

• Screen the MAR and home med list for opioids, alcohol, sedating antihistamines, and other benzodiazepines—perform medication reconciliation on admission and after every transfer
• Assess respiratory rate, oxygenation (pulse oximetry per protocol), sedation level, and mental status; review history of COPD, severe pulmonary disease, or sleep apnea
• Confirm allergy to clonazepam or other benzodiazepines; verify tablet strength, indication (seizure vs panic), and whether a taper is in place if therapy is being reduced
• Screen for acute narrow-angle glaucoma and significant liver disease—both are contraindications per labeling

Contraindications

• Acute narrow angle glaucoma (may be used in open-angle glaucoma on appropriate therapy per label)
• Clinical or biochemical evidence of significant liver disease
• History of sensitivity to benzodiazepines

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablets swallowed whole with water per labeling (0.5 mg scored; 1 mg and 2 mg unscored with K-shaped perforation on brand product).

• Controlled substance (Schedule IV): follow institutional controlled-drug counting, wasting, and secure storage requirements
• For panic disorder, one daily dose at bedtime may reduce daytime somnolence per labeling—verify prescriber intent
• When multiple anticonvulsants are ordered, expect additive CNS depression—stagger assessments and avoid duplicate sedating PRNs
• Increased salivation may occur—consider aspiration risk in patients who cannot handle secretions per label

• Reduced seizure frequency or panic attack burden when used for labeled indications—assess with patient report, seizure diary, and observation, not sedation alone
• Calmer affect without excessive somnolence, ataxia, or inability to arouse for conversation
• Stable respiratory rate and oxygenation; perform neurological assessment when sedation increases, mental status changes, or breakthrough seizures occur
• Loss of anticonvulsant effect may occur in some patients—notify prescriber rather than independently increasing dose

Respiratory depression with benzodiazepines—especially plus opioids or alcohol—can progress to coma and death. Clonazepam may cause respiratory depression in COPD or sleep apnea. Abrupt discontinuation can precipitate withdrawal seizures. Escalate immediately.

• Respiratory rate below facility threshold, shallow breathing, apnea, or new difficulty breathing—hold clonazepam, support airway per protocol, rapid response
• SpO₂ drop, cyanosis, or inability to arouse the patient—treat as respiratory emergency; consider opioid co-ingestion
• Excessive sedation, ataxia, or confusion after a dose or dose increase
• Paradoxical agitation, aggression, hallucinations, or psychosis—discontinue gradually per label; more likely in children and older adults
• New or worsening generalized tonic-clonic seizures when used in mixed seizure types—notify prescriber/neurology per labeling
• Breakthrough seizures, tremor, or autonomic instability after missed doses, abrupt stop, or flumazenil—urgent prescriber and neurology input

↔On a small screen, swipe or scroll sideways to see the full table.

Benzodiazepine overdosage ranges from drowsiness to coma. Severe cases may include respiratory depression. Combined overdose with opioids, alcohol, or other CNS depressants may be fatal. Markedly abnormal vital signs suggest polysubstance involvement.

Early signs

• Somnolence, confusion, dysarthria, ataxia, hypotonia, diminished reflexes
• Paradoxical agitation, irritability, or talkativeness (less common)
• Progressive respiratory depression and coma—especially with co-ingested opioids

Antidote and supportive care

Flumazenil is the specific benzodiazepine receptor antagonist indicated for complete or partial reversal of benzodiazepine sedation in overdosage management. It is an adjunct to airway management—not a substitute. Flumazenil may precipitate withdrawal and seizures, especially with chronic benzodiazepine use, mixed overdoses, or underlying seizure disorders; it is contraindicated when benzodiazepines were given for a potentially life-threatening condition (e.g., status epilepticus).

If opioids are co-involved, naloxone may reverse opioid-mediated respiratory depression per protocol—benzodiazepine effects may persist. Employ supportive measures including IV fluids and airway management per escalation pathways.

• Clonazepam vs clonidine—sound-alike and look-alike risk in verbal and written orders; independent double-check
• Clonazepam vs lorazepam vs diazepam—all are benzodiazepines but differ in half-life, potency, and taper plans; verify MAR name and strength
• Klonopin strength mix-ups—0.5 mg (scored), 1 mg, and 2 mg tablets; 2 mg is a high unit dose—independent double-check
• Clonazepam vs Klonopin wafer—if institution stocks multiple formulations, verify route and product
• Duplicate benzodiazepine therapy—home Klonopin plus ordered lorazepam PRN is a common sedation stack
• Opioid + benzodiazepine orders—two high-risk sedatives on one MAR; requires documented necessity and respiratory monitoring plan

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Respiratory rate, depth, and SpO₂—especially when opioids or alcohol are present or pulmonary disease is documented
• Sedation level (e.g., Pasero scale or facility tool), ability to arouse, and blood pressure for hypotension
• Mental status and anxiety/panic symptom response—sedation is not a proxy for therapeutic benefit
• Withdrawal signs if doses are delayed, reduced, or held: tremor, tachycardia, rebound anxiety, insomnia, seizures

Document

• Dose, route, time, indication, and patient response including respiratory status before and after
• Co-administered opioids or CNS depressants on the same shift; any hold and prescriber/pharmacist notification
• Controlled-drug count alignment; taper plan and patient education on why abrupt stops are dangerous

• Do not combine with alcohol, opioid pain medicines, or other sedating drugs unless your prescriber explicitly directs you—and report increased sleepiness immediately
• Do not drive or operate machinery until you know how clonazepam affects you, especially when starting or increasing dose or when taking opioids
• Never stop suddenly after regular use—withdrawal can be life-threatening (seizures); ask for a taper plan
• Keep medication secure (controlled substance); do not share tablets
• Seek urgent care for severe sleepiness, slow or troubled breathing, or inability to stay awake—and contact local poison control or toxicology services per your facility’s overdose guidance

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for clonazepam with a tabbed case (MAR, vitals, history, nursing notes), then priority action, cue recognition (SATA), respiratory trend interpretation, matrix urgency sorting, perioperative taper judgment, and overdose reversal cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.